Emilie B.
- Country
- France
- Department
- Service De Radiotherapie
Research Overview
- Phase III Randomized Study of Induction Chemotherapy with Modified DCF Regimen Followed by Chemoradiotherapy vs. Standard Chemoradiotherapy in Locally Advanced Anal Squamous Cell Carcinoma
- Evaluation of Pembrolizumab, Chemotherapy, and Radiotherapy in Advanced Non-Small Cell Lung Cancer: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 19 of 124 partner sites.
Specializations
Thoracic Oncology
The investigator specializes in treating advanced non-small cell lung cancer (NSCLC), with particular focus on innovative therapeutic approaches combining immunotherapy and radiation treatment. Their expertise extends to managing patients requiring first-line treatment with PD-1 inhibitors.
- Advanced Stage NSCLC Management
- Immunotherapy Integration
- Combination Treatment Strategies
Their work encompasses treatment optimization for stage IIIB/IIIC/IV lung cancer patients.
Gastrointestinal Oncology
The investigator focuses on treating locally advanced anal squamous cell carcinoma, developing therapeutic strategies that combine chemotherapy and radiation therapy. Their expertise includes the application of modified chemotherapy regimens in combination with standard treatment protocols.
- Anal Cancer Treatment
- Combined Modality Therapy
- Advanced Disease Management
Their therapeutic approach incorporates induction chemotherapy sequences with chemoradiotherapy for locally advanced disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.